Many GTPases such as Ras, Ral and Rho require post-translational farnestylation or geranylgeranylation for mediating malignant transformation. Dual farnesyltransferase (FT) (FTI) and geranylgeranyltransferase-I (GGT-1) inhibitors (GGTI) were developed as anticancer agents from based on an ethylenediamine scaffold. On the basis of a 4-fold substituted ethylenediamine scaffold, the inhibitors are structurally simple and readily derivatized, facilitating extensive structure-activity relationship studies. The most potent inhibitor is compound exhibited an in vitro hFTase IC50 value of 25 nM and a whole cell H-Ras processing IC50 value of 90 nM. Several of the inhibitors proved highly selective for hFTase over the related prenyltransferase enzyme geranylgeranyltransferase-I (GGTase-I). A crystal structure of an inhibitor cocrystallized with farnesyl pyrophosphate in the active site of rat FTase illustrates that the para-benzonitrile moiety is stabilized by a π-π stacking interaction with the Y361β residue, suggesting an importance of this component of the inhibitors.
许多GTP酶,如Ras、Ral和Rho,需要经过翻译后的法尼酰化或
戊二烯基化才能介导恶性转化。基于
乙二胺支架,开发了双法尼基转移酶(FT)(FTI)和
戊二烯基转移酶-I(GGT-1)
抑制剂(GGTI)作为抗癌药物。这些
抑制剂的结构简单,易于衍生,便于进行广泛的结构活性关系研究。其中最有效的
抑制剂在体外hFTase IC50值为25 nM,全细胞H-Ras处理IC50值为90 nM。其中几种
抑制剂对相关的
戊二烯基转移酶酶高度选择性。一种
抑制剂与法尼酰
焦磷酸在大鼠FTase的活性位点上共结晶的晶体结构表明,
对苯二腈基团与Y361β残基的π-π堆叠相互作用稳定,这表明该
抑制剂的这个组分很重要。